Sequoia Vaccines

Sequoia Vaccines, Inc. focuses on the discovery and development of novel vaccines to prevent bacterial infections, including recurrent urinary tract infections (UTIs), as well as the use of small molecules to treat certain cancers and lung infections associated with cystic fibrosis. Sequoia Vaccines' primary clinical candidate, SEQ-400, is an investigational vaccine for the prevention of recurrent urinary tract infections, which received Fast Track designation from the U.S. Food and Drug Administration (FDA) in December 2017. Sequoia Vaccines plans to conduct a UTI observational trial in 2023, aiming to identify and define a patient population with culture-verified recurrent UTIs to participate in a subsequent Phase 2 efficacy trial of SEQ-400. Participating patients will serve as their own controls, comparing UTI incidence before and after vaccination with SEQ-400. SEQ-400 is designed to generate antibodies capable of reducing bacterial attachment and colonization in the human bladder, thereby preventing urinary tract infections.